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Abstract 
Objectives:
The characteristics of paediatric neuromyelitis optica spectrum 
disorder (NMOSD) may indicate the degree of disability and identify 
factors that predict the response to treatment.
Materials & Methods
Among 114 NMOSD patients in an acquired demyelinating 
syndromes registry at the Sina Hospital, in Tehran, Iran, 10 paediatric 
NMOSD patients with longitudinal follow-up from 2005 to 2016 
were retrospectively identified. The median time between disease 
onset and diagnosis was 18 months (range 1-108 months).
Results
All patients had a relapsing course, which resulted in disability in six 
with severe visual impairment and functional blindness in one and 
impaired ambulation in five patients during follow-up. Azathioprine 
(AZA) was first drug of choice for prophylaxis, but in five patients 
new attacks occurred and therapy was switched to rituximab (RTX) 
with no further relapses after median two years (range 1-3 y) follow-
up.
Conclusion
Paediatric onset of NMOSD was associated with severe attacks and 
poor response in 50% of cases to decrease the relapse rate. 
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Introduction 
Neuromyelitis optica spectrum disorder (NMOSD) 
is a rare autoimmune inflammatory disease of 
the central nervous system (1). In most cases, 
an autoantibody to the astrocytic water channel 
protein aquaporin-4 (AQP4-IgG) can be detected 
(2). AQP4-IgG causes complement-dependent 
astrocyte injury, inflammation, and consequent 
demyelination besides axonal damage (2, 3). A 
high relapse rate and disability accumulation in 
NMOSD can cause severe neurological disabilities, 
which can potentially be prevented or modified by 
appropriate treatment (3). 
An early onset of NMOSD is defined as disease 
onset prior to 18 years (y) of age (4). The paediatric 
onset of NMOSD comprises 4% of all cases (4). 
Paediatric NMOSD rarely occurs before the age 
of nine, with a variable median age (5, 6). The 
Paediatric Working Group for Neuromyelitis 
optica spectrum disorder (NMOSD) has stated 
that adult consensus criteria are applicable to 
paediatric patients (1). However, some differences 
have been noted such as a lower female–male 
ratio (3:1) compared with adults (9:1), more cases 
with a monophasic course, and less specificity 
of a longitudinally extensive transverse myelitis 
(LETM) lesion on spinal cord MRI (7). 
We aimed to review and analyse detailed data 
of paediatric onset of NMOSD cases including 
clinical manifestations and treatment responses, the 
data underscore the presence of severe disability 
in paediatric patients and may assist in the 




Of the 114 NMOSD patients registered in the Sina 
Hospital NMOSD Clinic of the Tehran University 
of Medical Sciences, Tehran, Iran, 10 showed 
paediatric onset ( 18 y of age). These cases were 
diagnosed from 2005 to 2016. Their clinical 
symptoms, laboratory data and MRI findings were 
reviewed and questionnaires were used to provide 
long-term retrospective data. All patients had been 
diagnosed according to last international consensus 
criteria of NMOSD (1).
Laboratory methods
Determination of AQP4-IgG was carried out using 
an indirect immunofluorescence (IFA) assay with 
HEK293 cells transfected with recombinant human 
full-length AQP4 gene starting at a 1:10 dilution 
(Euroimmun, Lübeck, Germany) (8).
Ethics approval
Oral and written informed consent was obtained 
from all participants. The study was carried out in 
accordance with the Tehran University of Medical 
Sciences Ethical Committee guidelines.
Statistical analysis
Statistical differences were tested using the 
Wilcoxon rank sum test for two-group comparisons 
and the Fisher exact test for group comparisons 
of categorical variables. A P-value < 0.05 was 
considered significant.
Results
Demographic data and clinical course
The demographic and clinical characteristics of the 
patients are depicted in Table 1. Ten patients (seven 
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AQP4-IgG positive) aged under 18 yr at disease 
onset were included. The female–male ratio was 
4:1. The median age at disease onset was 13 y 
(range: 8–17 y). The median age of the patients at 
the disease diagnosis was 14 yr (range: 10-26 yr). 
Thirty-four relapses were recorded for all patients. 
Clinical presentation
The initial presentation in four of the patients was 
optic neuritis (ON); in one, simultaneous ON/ 
transverse myelitis (TM); in three, LETM; and in 
two, area postrema syndrome (APS). ON in these 
cases was characterised by severe visual acuity, in 
three with unilateral ON, and in one with sequential 
bilateral ON. Visual acuity was lowered to less or 
equal to 20/200 in two patients and in one patient 
ended up with a permanent unilateral blindness 
despite intensive treatment. The disease followed 
a relapsing course in all 10 patients. The median 
time between disease onset and diagnosis was 18 
months (range 1-108 months).
The second attack was ON (seven) and TM 
(three), all with LETM. During follow-up, acute 
TM occurred in two patients. Acute TM/LETM 
caused tetraparesis in two patients, paraparesis in 
seven patients, dysesthesia in all patients. Patients 
were followed for median two y (range 2-4 y) after 
diagnosis.
Neuroimaging findings
Brain MRIs after the first attack were normal in 
seven cases. The three cases with abnormal brain 
MRI at the first presentation showed nonspecific 
scattered white matter subcortical lesions (one 
patient), area postrema involvement (one patient), 
and diencephalic lesion (one patient). The brain 
MRI follow-up one year later was normal in seven 
and nonspecific in three patients. 
Spinal cord MRI in two patients demonstrated 
cervical LETM reaching into the brainstem with 
area postrema involvement, while one patient 
showed thoracic LETM at the onset of NMOSD. 
During follow-up, eight patients had LETM. 
Notably, the median length of the LETM was 9 
(range 7-11) vertebral body heights in males and 
7.5 (range 3-12) in females. LETM was noted in 
the cervical MRIs of one patients, the thoracic 
MRIs of three patients, and the cervicothoracic 
MRIs of four patients. 
Lab data
AQP4-IgG was positive in seven patients with 
ELISA and IIF assays. Anticardiolipin antibodies 
(IgG and IgM), antinuclear antibodies (ANA), 
anti-dsDNA antibodies, anti-Sjögren’s-syndrome-
related antigens A and B, also called anti-Ro and 
anti-La angiotensin converting enzyme (ACE), 
and serum human T-lymphotropic virus (HTLV) 1 
and 2 antibodies were negative in all patients and 
no coexisting autoimmunity or family history of 
autoimmune disease was observed. 
Treatment
Initial acute attack was treated with high-dose 
intravenous methylprednisolone (IVMP) (30 mg/
kg/d for 5 days up to a maximum of 1000 mg 
daily) (9). In 50% (five) of the patients, there was 
no improvement from pulse therapy alone and 
plasma exchange (PLEX) was introduced. Despite 
PLEX, visual acuity decreased in four patients to 
hand motion. Full recovery was achieved by PLEX 
in one case after the IVMP failure.
All patients received azathioprine (AZA) (2–3 
mg/kg) (9) as the first line of therapy for relapse 
prevention. Although AZA was well tolerated, it did 
not prevent further exacerbations in five patients 
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every six months over the next two years. The 
median annual relapse rate changed from 1 (range 
0.6-2) before preventive therapy to 0.5 (range 
0-2) after the therapy with azathioprine (Table 2). 
Five of the patients had their treatment switched 
to rituximab (RTX) because of new relapse on 
treatment with azathioprine, while no further 
relapse occurred with RTX in these five patients 
within two years (Table 2). RTX was administered 
as 1 g given IV 2 weeks apart and then repeated 
every 6 months. No severe complications occurred 
with RTX. The median expanded disability status 
scale (EDSS) before preventive therapy was 3 
(0-5 range) and decreased to 2.5 (range 0-5) after 
preventive therapy (Table 3). 
Table 1. Demographic and clinical characteristics of the patients 
Variable Male Female
Total number 2 8
Median age at onset/year-old 11(range 9-13) 13.5 (range 8-17)
Median duration of diseases before 
diagnosis/months
9 (range 6-12 months) 24(range 1-108 months)
Positive anti-AQP4 Ab 1 5
Abnormal brain MRI 1 6
Cervical LETM/patients 0 1
Thoracic LETM/patients 1 2
Cervicothoracic LETM/patients 1 3
Median length of LETM/Segment 9 (range 7-11 segment) 7.5(range 3-12 segment)
LETM = Longitudinal extensive transverse myelitis
Table 2. Annualized relapse rate before and after preventive therapy
ARR/Patient/year P1 P2 P3 P4 P5 P6 P7 P8 P9 P10
ARR before preventive therapy 0.6 0.8 1 1 2 2 1 1 1.5 1
ARR after azathioprine 2 2 0 1 0 0 0 1 0 1
ARR after rituximab 0 0 0 0 0
ARR = Annual relapse rate
Discussion
This retrospective case series with longitudinal 
follow-up aimed to describe paediatric NMOSD 
including clinical, neuroimaging characteristics, 
and treatment responses. The data indicated 
that the onset of NMOSD during childhood was 
associated with severe attacks with irreversible 
disability despite intensive treatment including 
PLEX. Immunosuppressive treatment seemingly 
decreased the relapse rate, however, a poor response 
to AZA was observed in half of the cases, leading 
to the use of RTX, being a more potent therapy. 
Overall, these findings emphasize the importance 
of patient identification, which may lead to early 
and effective treatment and define key areas for 
future research. 
A heterogeneous pattern of clinical paediatric 
NMOSD manifestations was observed, including 
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ON, TM/LETM, and brainstems lesions. LETM 
tended to occur during the course, not at onset, 
of paediatric NMOSD. The disease followed 
a relapsing course in all patients and resulted 
in disability with severe visual impairment or 
functional blindness; it also impaired ambulation 
during follow-up. In all the 10 patients, 
immunosuppressive therapy was started with 
AZA. Five of the patients tolerated AZA well with 
no further attacks, but in five other patients new 
attacks occurred and immunosuppressive therapy 
was switched to RTX. No further relapses occurred 
for two years in the five patients on treatment with 
RTX. 
RTX is an anti-CD20 chimeric monoclonal antibody 
that depletes B cells and is used in autoimmune 
and inflammatory CNS disorders including 
NMOSD (10). In adult NMOSD one prospective 
and 3 retrospective, RTX reduced the annualized 
relapse rate (10). One prospective paediatric study 
of RTX reported that RTX was effective in relapse 
prevention (11). In the present study after starting 
preventive treatment, the median annual relapse 
rate decreased. Although the lowering of EDSS 
was not significant after preventive treatment 
probably because of the small sample size, the 
median relapse rate decreased significantly. The 
current case series is the first Iranian report on 
RTX treatment of paediatric NMOSD.  
In Conclusion, paediatric onset of NMOSD 
does occur. As a consequence, NMOSD may be 
considered a differential diagnosis for paediatric 
MS. The clinical phenotype was compatible 
with other reports of paediatric NMOSD cases. 
Disability occurred incrementally as a result of 
attacks. It seems that the immunosuppressive 
treatment for paediatric NMOSD patients may 
decrease the relapse rate and that RTX is a superior 
treatment option. Larger studies are required to 
further evaluate long-term disability in this regard.
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